Healthcare mergers and acquisitions activity in the second quarter of 2026 (Q2:26) saw a divergence between transaction volume and total value, with disclosed spending reaching $95.3 billion across 78 transactions. According to data from LevinPro HC, while the number of publicly announced deals dropped 23% year-over-year to 459 from 503 in Q2:25, the total capital deployed nearly tripled from $28.7 billion in the same period last year. This surge in value was primarily driven by an increase in "mega-deals," defined as transactions exceeding $1 billion, which rose to 21 deals in Q2:26 from 13 in Q1:26.

The most significant transaction was Sun Pharmaceutical Industries Ltd.’s $11.75 billion acquisition of Organon & Co., a pharmaceutical company specializing in reproductive medicine and psychiatry. Merck also made a major move, spending $11.3 billion to acquire Bio-Techne Corporation, a provider of life science tools. Bio-Techne reported full-year fiscal 2025 revenue of $1.22 billion and EBITDA of $213 million. This marked Merck’s second large-scale acquisition of the year, following its $6.7 billion purchase of Terns Pharmaceuticals Inc. in March.

Sector Performance

Physician Medical Group (PMG) remained the most active segment, accounting for 106 transactions or 23% of total volume, though this was down from 124 deals in Q1:26. Dental services attracted the most investor interest among specialties with 54 deals, followed by internal medicine (7) and pediatrics (6). The healthcare services space also saw activity in Medical Outpatient Buildings (51 deals), Home Health & Hospice (20), and Behavioral Health Care (18).

In healthcare technology, eHealth led with 58 deals, representing a 25% decline from Q2:25. Within this sector, AI-driven services such as revenue cycle management (10 deals) and Medical Practice Management Software (9 deals) were prominent. The Medical Device sector recorded 27 deals, an increase from 21 in Q1:26.

Investor Trends

Private equity firms maintained consistent deal volume, reporting 151 deals in Q2:26 compared to 150 in Q1:26, but their market share increased to 33% from 27%. PMG accounted for 39% of private equity activity with 59 deals, while eHealth attracted 21 private equity transactions. Year-over-year, health systems deals rose to 30 from 22, and real estate investment firm deals increased to 37 from 33. Hospitals accounted for less than 50% of health systems’ deal volume, with only 13 transactions, as systems increasingly purchased non-hospital assets like outpatient centers and urgent care facilities.

What the Numbers Show

The data indicates a shift toward consolidation through fewer, larger transactions rather than broad-based acquisition activity. While overall deal count contracted significantly, the concentration of capital in mega-deals suggests that strategic buyers are prioritizing scale and high-value targets over smaller opportunistic purchases. This trend is evident in the doubling of billion-dollar deals quarter-over-quarter, which disproportionately influenced the total market value despite the decline in transaction frequency.